About the event
Join us in Vienna for ISPOR Europe 2026, the premier global conference in Europe for Health Economics and Outcome Research (HEOR). As a proud ISPOR Mission Partner, we’re excited to connect with global leaders to advance the future of healthcare together.
Visit us at booth 715 onsite!
Visit us at booth 715 onsite!
Speaker sessions
Educational symposium
One assessment, many decisions: The future of country-level HTA after JCA
Date: Monday, 9 November 2026
Time: 3:15 – 4:15 pm
Moderator: Ruairi O'Donnell, PHD. Cencora, London, United Kingdom
Speakers:
Time: 3:15 – 4:15 pm
Moderator: Ruairi O'Donnell, PHD. Cencora, London, United Kingdom
Speakers:
- Anne Willemsen, MSc. Zorginstituut Nederland, Diemen, Netherlands
- Anna Shopova, MBA. AMGEN, Zug, Switzerland
- Neil Grubert, MA. Neil Grubert Consulting, Basildon, United Kingdom
- Antonella Maria Giovanna Cardone, MBA. Cancer Patients Europe, Brussels, Belgium
Fast facts session
The next generation of HEOR: Career pathways in an AI-augmented field
Date: Tuesday, 10 November, 2026
Time: 11:45 - 12:15pm
Moderator: Ghayath Janoudi, PhD, MD, Loon, Canada
Speakers:
Time: 11:45 - 12:15pm
Moderator: Ghayath Janoudi, PhD, MD, Loon, Canada
Speakers:
- Anggie Wiyani, MSc, Novartis, United Kingdom
- Erika Wissinger, PhD, Cencora, United States
- Vandana Ayyar Gupta, PhD, NICE, United Kingdom
Issue panel
The triple challenge: How do global pricing dynamics, with US MFN policy, China’s rise, and European policies converge and impact European competitiveness?
Date: Wednesday, 11 November 2026
Time: 10:00 - 11:00 am
Moderator: Casper Paardekooper, MSc Cencora, Voorburg, Netherlands
Speakers:
Time: 10:00 - 11:00 am
Moderator: Casper Paardekooper, MSc Cencora, Voorburg, Netherlands
Speakers:
- Neil Grubert, MA. Neil Grubert Consulting, Basildon, United Kingdom
- Eelko den Breejen, Pfizer (Global), Capelle a.d. IJssel, Netherlands
- Ferenc Marofka, MSc., Brussels, Belgium
Don’t miss our poster presentations during ISPOR Europe 2026:
- The cost-effectiveness of imlifidase for desensitisation treatment of highly sensitised adult kidney transplant patients in Spain
- Long-term economic impact of gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderatelysevere haemophilia B in Spain
- The economic burden of early-stage HR+/HER2- breast cancer (BC) in Spain. A cost-of-illness study
- Cost-utility analysis of sparsentan for the treatment of immunoglobulin A nephropathy: a comparison of sparsentan versus irbesartan and modified-release budesonide in Spain
- Economic evaluation of sparsentan versus targeted-release formulation budesonide in patients with primary immunoglobulin A nephropathy in Austria
- Assessment of medicines in Catalonia (Spain) in 2025: economic evidence and gaps
- Time from AEMPS authorization to the first P&R assessment in 2025 and last available CIPM decision in new medicines in Spain
- Reassessing orphan drugs: effects of the €30 million threshold on added benefit and pricing in Germany
- Navigating HTA and reimbursement in the DACH region - a comparative analysis of national processes and evidence requirements with strategic implications for market access in Germany, Austria and Switzerland
- Defining requirements for evidence transfer from adult to pediatric populations: insights from the German early benefit assessment
- The environmental impact of emicizumab: an analysis of dual distribution and dispensing pathways for hemophilia A in France
- Environmental impact of switching from intravenous to subcutaneous infliximab in inflammatory bowel disease: a carbon footprint analysis in France
- Project Orbis participation in the context of evolving U.S. drug pricing policies
- 3701 - Biosimilar availability and uptake across six European countries: uneven utilization despite expanding access
- Insights from a national cancer registry: clinical characteristics and treatment pathways of metastatic breast cancer patients in Germany - a retrospective analysis of ZfKD data
- Same generation, different state: regional disparities in sick leave across baby boomers, Gen-X, millennials, and Gen-Z in Germany
- Sick in the city? Regional differences and causes of sick leave in Germany: claims data insights and analytical opportunities
- Epidemiology and treatment patterns of neuroendocrine tumors in Germany: insights from a national cancer registry
- Clinical heterogeneity in indolent systemic mastocytosis: a German claims data analysis supporting the need for multidisciplinary care
- Evolving coding practices for primary IgA nephropathy in German claims data: evidence from 2022–2024
- Healthcare resource utilisation and costs associated with neutropenia/leukopenia-related hospitalisations in kidney transplant recipients receiving valganciclovir prophylaxis in Germany: a claims database study
- Selection and use of primary endpoints in onco-hematology: a disease-specific analysis of clinical evidence to support regulatory and reimbursement decisions
- A multidimensional framework to manage regional strategic planning for advanced therapy medicinal products
Additional resources
Cencora solution
EU Health Technology Assessment (HTA) consulting
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level.
Article
Leaders in focus: Exclusive interviews from ISPOR Europe 2025
At ISPOR Europe 2025 in Glasgow, a leading conference for Health Economics and Outcomes Research (HEOR), we connected with global healthcare leaders to explore pressing challenges, emerging opportunities, EU HTA complexities, country-specific strategies, and policy changes shaping innovation and patient access.
Meet with us at ISPOR Europe
Our consultative approach and extensive reach across healthcare give us access to the best insights in the industry - insights we leverage to help commercialization challenges for our partners and patients they serve. Schedule a meeting with our team at ISPOR to learn more.
